JANESVILLE, Wis.--(BUSINESS WIRE)--SHINE Medical Technologies LLC today announced the appointments of Jean Rogers, Ph.D., an environmental, social and governance (ESG) expert, and Tamanna Bembenek, Ph.D., a global marketing leader, to the company’s board of directors.
Dr. Rogers brings to SHINE’s board more than two decades of experience advising companies on environmental, social and governance (ESG) criteria, and long-term value creation. She is the founder and former chief executive officer of the Sustainability Accounting Standards Board, or SASB.
Under Dr. Rogers’ leadership, the SASB developed sustainability accounting standards for 79 industries and launched education programs in sustainability accounting. Today, SASB is the gold standard for disclosure of material ESG risks, recognized by long-term institutional investors around the world.
Dr. Rogers also is an advisor to the Long-Term Stock Exchange, or LTSE, a national stock exchange approved by the U.S. Securities and Exchange Commission in 2019. The exchange supports companies and investors committed to the creation of long-term shareholder value.
Dr. Rogers fills the seat of Brad Wucherpfennig, who has become a board observer.
“Jean joins our board of directors at a crucial, exciting time in our history,” said Greg Piefer, founder and CEO of SHINE. “Jean’s work to improve the fairness and efficiency of the capital markets through socially conscious, long-term value creation is groundbreaking. We look forward to Jean’s expertise, experience and insight, while we thank Brad for his years of thoughtful service to the board and SHINE.”
“SHINE’s commitment to a long-term vision for its fusion-based technology is a cornerstone of transforming medicine and energy in a way that is consistent with a net zero carbon economy,” Dr. Rogers said. “I look forward to working on SHINE’s efforts to build long-term value, while continuing our passionate commitment to strong environmental, social and governance performance.”
Dr. Rogers is a visiting fellow at the Harvard Kennedy School, where she works with social entrepreneurs. She earned undergraduate and master’s degrees from Manhattan College, Riverdale, N.Y. She earned a doctorate in environmental engineering from the Illinois Institute of Technology. She was a post-doctoral fellow at Harvard University.
Tamanna Bembenek, Ph.D., is a senior health care executive with broad experience in medical devices and radiopharmaceuticals. She has more than 20 years of global experience in marketing, sales, product development, strategy and commercialization.
Dr. Bembenek has a strong track record of developing partnerships with biotechnology and pharmaceutical companies, patient advocacy groups, professional scientific societies and government agencies in the United States and around the world. These partnerships have focused on improving awareness of and access to health care.
Most recently, she served as the senior vice president of health systems marketing at Royal Philips, overseeing all of the company’s health care segment. Prior to that, she held various global marketing and product leadership positions within precision diagnostics at Philips. Before joining Philips, Dr. Bembenek spent more than a decade in product management and marketing in diagnostic imaging at GE Healthcare, including global leadership positions in PET/SPECT and CT imaging for neurological applications, radiopharmaceuticals and point-of-care ultrasound.
Dr. Bembenek earned her bachelor’s degree from Lake Forest College and her doctorate in biochemistry from the Texas A&M Health Science Center.
“Tamanna’s experience and expertise provides our board and the company with a unique, global perspective,” Piefer said. “Her work to ensure that we can effectively engage with and deliver SHINE’s story to key markets is already making a difference. Tamanna’s continued insight will be critical to SHINE as we execute our commercialization plans.”
Dr. Bembenek has been serving on the board since her election to it last year.
“It is a pleasure to help craft the strategy for articulating SHINE’s vision for fusion technology and how it can solve the world’s biggest challenges,” Dr. Bembenek said. “Our technology and vision are the keys to creating and sustaining long-term value. As markets continue to evolve, we will ensure that SHINE’s story enables us to create that value in both existing and emerging markets.”
About SHINE Medical Technologies
SHINE is a nuclear technology company committed to improving the lives of patients around the world. The company is focused initially on the commercialization of medical isotopes, including molybdenum-99, a diagnostic isotope used to diagnose heart disease, cancer and other diseases, and lutetium-177, a therapeutic isotope that holds the promise of significantly improving the outcomes for some cancer patients. SHINE has created isotope production processes that will deliver products to benefit physicians and patients and help solve critical supply problems in the United States and markets in Europe and around the world. SHINE has a long-term strategy to solve some of humanity’s biggest problems and advance our vision for progressively broad and impactful uses of nuclear technology. For more information, please visit our website at www.shinemed.com.